Previous 10 | Next 10 |
2023-03-29 12:12:50 ET BridgeBio Pharma ( NASDAQ: BBIO ), a potential buyout target, added ~18% on Wednesday, recording the second-best intraday gain for the year, amid market rumors that the company has decided to pull out of a conference next week. BridgeBio ( BBIO...
2023-03-24 17:28:03 ET Gainers: BridgeBio Pharma ( BBIO ) +14% . Iovance Biotherapeutics ( IOVA ) +10% . Iris Energy ( IREN ) +5% . Alphabet ( GOOGL ) +4% . Zions Bancorporation ( ZION ) +3% . Losers: CRISPR T...
2023-03-24 17:06:23 ET BridgeBio Pharma rose 10% in regular trading and jumped another 14% in after hours on a report that the developer of treatments for genetic diseases is garnering takeover interest from big pharma companies. Some large drug companies are evaluating a po...
2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...
2023-03-23 08:29:24 ET BridgeBio Pharma ( NASDAQ: BBIO ) said the first patient with non-small cell lung cancer (NSCLC) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's ( NYSE: BMY ) Opdivo (nivolumab) to treat advanced solid tumors with KR...
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mu...
2023-03-21 16:57:51 ET Gainers: Maxpro Capital Acquisition ( JMAC ) +31% . Telesis Bio ( TBIO ) +10% . BridgeBio Pharma ( BBIO ) +4% . Hawaiian Holdings ( HA ) +2% . ProFrac Holding ( ACDC ) +2% . Losers: Adap...
- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺ DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I patients - BridgeBio also shared 15-month results from its ongoing Pha...
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an oral pr...
2023-03-08 11:54:50 ET During Wednesday's midday trading, the major U.S. equity indexes were mixed, as Wall Street tried to recover following hawkish comments by Federal Reserve Chairman Jerome Powell the day before. Looking at the individual stocks, Korn Ferry ( NYSE: KFY )...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...